EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 109 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,426,254 | -43.1% | 280,688 | -29.9% | 0.00% | -50.0% |
| Q2 2023 | $7,785,763 | -40.1% | 400,499 | -12.6% | 0.00% | -50.0% |
| Q1 2023 | $13,001,994 | +127133.5% | 458,312 | +31.1% | 0.00% | +33.3% |
| Q4 2022 | $10,219 | -99.9% | 349,606 | -1.7% | 0.00% | -25.0% |
| Q3 2022 | $9,401,000 | -33.4% | 355,759 | +12.0% | 0.00% | -20.0% |
| Q2 2022 | $14,114,000 | -6.4% | 317,676 | +4.2% | 0.01% | 0.0% |
| Q1 2022 | $15,084,000 | +2.2% | 304,784 | +5.2% | 0.01% | +25.0% |
| Q4 2021 | $14,753,000 | -5.7% | 289,729 | +3.2% | 0.00% | -20.0% |
| Q3 2021 | $15,653,000 | +21.4% | 280,620 | -6.8% | 0.01% | +25.0% |
| Q2 2021 | $12,890,000 | -5.8% | 301,177 | -8.2% | 0.00% | -20.0% |
| Q1 2021 | $13,686,000 | -4.3% | 327,907 | +6.8% | 0.01% | 0.0% |
| Q4 2020 | $14,297,000 | +12.8% | 307,010 | +2.9% | 0.01% | 0.0% |
| Q3 2020 | $12,671,000 | -10.4% | 298,292 | +1.2% | 0.01% | -16.7% |
| Q2 2020 | $14,142,000 | +3.8% | 294,740 | -0.5% | 0.01% | -14.3% |
| Q1 2020 | $13,621,000 | -21.6% | 296,119 | +2.4% | 0.01% | +16.7% |
| Q4 2019 | $17,378,000 | +12.4% | 289,244 | +5.9% | 0.01% | 0.0% |
| Q3 2019 | $15,455,000 | +11.9% | 273,210 | +10.1% | 0.01% | +20.0% |
| Q2 2019 | $13,811,000 | +107.8% | 248,048 | +88.5% | 0.01% | +66.7% |
| Q1 2019 | $6,645,000 | +25.3% | 131,605 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $5,302,000 | -8.1% | 131,605 | +58.1% | 0.00% | 0.0% |
| Q3 2018 | $5,771,000 | +44.3% | 83,246 | +57.6% | 0.00% | 0.0% |
| Q2 2018 | $3,998,000 | +154.0% | 52,836 | +76.9% | 0.00% | +100.0% |
| Q1 2018 | $1,574,000 | -3.0% | 29,876 | -1.6% | 0.00% | 0.0% |
| Q4 2017 | $1,622,000 | -16.8% | 30,372 | -7.1% | 0.00% | 0.0% |
| Q3 2017 | $1,949,000 | -23.5% | 32,686 | +1.2% | 0.00% | 0.0% |
| Q2 2017 | $2,548,000 | +313.0% | 32,298 | +334.3% | 0.00% | – |
| Q1 2017 | $617,000 | +4.6% | 7,437 | 0.0% | 0.00% | – |
| Q4 2016 | $590,000 | – | 7,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |